Q2 Earnings Forecast for VERV Issued By Lifesci Capital

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2025 earnings estimates for Verve Therapeutics in a research note issued to investors on Tuesday, June 17th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.71) per share for the quarter. Lifesci Capital has a "Hold" rating and a $12.00 price objective on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. Lifesci Capital also issued estimates for Verve Therapeutics' Q3 2025 earnings at ($0.71) EPS and Q4 2025 earnings at ($0.70) EPS.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.36. The firm had revenue of $32.98 million for the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%.

VERV has been the topic of a number of other reports. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Guggenheim increased their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. HC Wainwright downgraded shares of Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 price objective for the company. in a research report on Wednesday. Jefferies Financial Group cut Verve Therapeutics from a "buy" rating to a "hold" rating and cut their target price for the stock from $28.00 to $11.00 in a research note on Wednesday. Finally, Canaccord Genuity Group downgraded Verve Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their target price for the company from $39.00 to $13.00 in a report on Tuesday. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $14.75.

Verve Therapeutics Stock Performance

NASDAQ:VERV traded down $0.26 during mid-day trading on Thursday, reaching $11.12. 13,050,292 shares of the company's stock were exchanged, compared to its average volume of 2,356,714. Verve Therapeutics has a one year low of $2.86 and a one year high of $11.41. The business's fifty day simple moving average is $5.18 and its two-hundred day simple moving average is $5.88. The firm has a market capitalization of $991.24 million, a PE ratio of -5.27 and a beta of 1.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BVF Inc. IL boosted its holdings in shares of Verve Therapeutics by 962.2% during the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock valued at $38,939,000 after acquiring an additional 6,254,050 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its position in Verve Therapeutics by 57.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock valued at $21,372,000 after purchasing an additional 1,382,176 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Verve Therapeutics during the first quarter valued at about $12,648,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Verve Therapeutics by 5.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,491,949 shares of the company's stock valued at $11,389,000 after purchasing an additional 139,350 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Verve Therapeutics by 18.5% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock worth $10,423,000 after purchasing an additional 288,678 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.